Protagonist Therapeutics CFO sells 58,629 shares

The CFO’s common-stock acquisitions and sales were reported under a Rule 10b5-1 plan adopted June 30, 2026.

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. (PTGX) CFO Asif Ali exercised options for 58,629 common shares on September 30, 2026, at four exercise prices: $38.98, $23.42, $19.19 and $12.17 per share. He sold 58,629 shares in two reported transactions: 12,595 shares at a weighted-average price of $141.77 per share and 46,034 shares at $141.78 per share. The reported common-stock acquisitions and sales were effected under a Rule 10b5-1 trading plan adopted June 30, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 58,629 shares ($6.92M approx. pre-tax spread)

Exercise and Sale 10 txns

Insider Ali Asif

Role Chief Financial Officer

Sold 58,629 shs ($8.31M)

Approx. gross sale proceeds $8.31M

Approx. exercise cost $1.39M

Approx. pre-tax spread $6.92M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F4	9,229	$0.00	$0.00
Exercise	Stock Option (right to buy) F5	28,438	$0.00	$0.00
Exercise	Stock Option (right to buy) F6	15,650	$0.00	$0.00
Exercise	Stock Option (right to buy) F7	5,312	$0.00	$0.00
Exercise	Common Stock F1	9,229	$38.98	$360K
Exercise	Common Stock F1	28,438	$23.42	$666K
Exercise	Common Stock F1	15,650	$19.19	$300K
Exercise	Common Stock F1	5,312	$12.17	$65K
Sale	Common Stock F1, F2	12,595	$141.77	$1.79M
Sale	Common Stock F1, F3	46,034	$141.78	$6.53M

Holdings After Transaction: Stock Option (right to buy) — 155,238 contracts (Direct); Common Stock — 59,003 shares (Direct)

Footnotes (7)

1. F1. The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
4. F4. The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
5. F5. The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
6. F6. The stock option is fully vested.
7. F7. The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Key Figures

Options exercised at $38.98: 9,229 shares at $38.98 per share Options exercised at $23.42: 28,438 shares at $23.42 per share Options exercised at $19.19: 15,650 shares at $19.19 per share +3 more

6 metrics

Options exercised at $38.98 9,229 shares at $38.98 per share September 30, 2026

Options exercised at $23.42 28,438 shares at $23.42 per share September 30, 2026

Options exercised at $19.19 15,650 shares at $19.19 per share September 30, 2026

Options exercised at $12.17 5,312 shares at $12.17 per share September 30, 2026

Shares sold at $141.77 12,595 shares; weighted-average sale price $141.77 per share September 30, 2026

Shares sold at $141.78 46,034 shares; weighted-average sale price $141.78 per share September 30, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price per share, Stock Option (right to buy)

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price per share financial

"The price reported represents the weighted average sale price per share."

Stock Option (right to buy) financial

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PTGX shares did CFO Asif Ali sell, and at what prices?

On September 30, 2026, CFO Asif Ali sold 12,595 shares at a weighted-average $141.77 per share and 46,034 shares at a weighted-average $141.78 per share. The sales were effected under a Rule 10b5-1 trading plan adopted June 30, 2026.

What PTGX options did CFO Asif Ali exercise?

On September 30, 2026, he exercised options for 9,229 shares at $38.98 per share, 28,438 at $23.42, 15,650 at $19.19 and 5,312 at $12.17.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:10 PM Accepted by SEC EDGAR 10/02/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Asif

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		M(1)		9,229	A	$38.98	68,232	D
Common Stock	09/30/2026		M(1)		28,438	A	$23.42	96,670	D
Common Stock	09/30/2026		M(1)		15,650	A	$19.19	112,320	D
Common Stock	09/30/2026		M(1)		5,312	A	$12.17	117,632	D
Common Stock	09/30/2026		S(1)		12,595	D	$141.77(2)	105,037	D
Common Stock	09/30/2026		S(1)		46,034	D	$141.78(3)	59,003	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$38.98	09/30/2026		M			9,229	(4)	01/01/2035	Common Stock	9,229	$0	29,291	D
Stock Option (right to buy)	$23.42	09/30/2026		M			28,438	(5)	01/01/2034	Common Stock	28,438	$0	49,562	D
Stock Option (right to buy)	$19.19	09/30/2026		M			15,650	(6)	04/17/2032	Common Stock	15,650	$0	51,150	D
Stock Option (right to buy)	$12.17	09/30/2026		M			5,312	(7)	01/15/2033	Common Stock	5,312	$0	25,235	D

Explanation of Responses:

1. The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

4. The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

5. The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

6. The stock option is fully vested.

7. The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)